Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2703302 | 0.78 | — | — | |
| SCHEMBL23648172 | 0.71 | — | — | |
| SCHEMBL23780299 | 0.71 | — | — | |
| SCHEMBL4267205 | 0.65 | — | — | |
| SCHEMBL4868123 | 0.64 | TSHR (0.36) | TSHR | |
| SCHEMBL456363 | 0.62 | TSHR (0.42) | TSHR | |
| SCHEMBL19550942 | 0.59 | — | — | |
| SCHEMBL1029023 | 0.59 | — | — | |
| SCHEMBL52052 | 0.58 | — | — | |
| SCHEMBL1559461 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006016903-A2 | 1, 2,4-TRIOXANES AND 1, 2, 4-TRIOXEPANES | ROMARK LABORATORIES, L.C. (US) | 2006-02-16 | — | — | WO | claimed |
| US-20050256184-A1 | 1,2,4-Trioxanes and 1,2,4-trioxepanes | O'NEILL PAUL M | 2005-11-17 | — | — | US | claimed |
| CN-101400708-B | Process for purifying resorbable polymers from residual monomers | PURAC BIOCHEM B.V. (NL) | 2012-02-01 | — | — | CN | disclosed |
| CN-101400708-A | Process for purifying resorbable polymers from residual monomers | PURAC BIOCHEM BV (NL) | 2009-04-01 | — | — | CN | disclosed |
| US-7417156-B2 | Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers | JOHNS HOPKINS UNIVERSITY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20060142377-A1 | Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high selectively, stability and efficacy and methods of making the same | JOHNS HOPKINS UNIVERSITY-LICENSE & TECHNOLOGY DEVE (US) | 2006-06-29 | — | — | US | disclosed |
| WO-2006016903-A2 | 1, 2,4-TRIOXANES AND 1, 2, 4-TRIOXEPANES | ROMARK LABORATORIES, L.C. (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20050256184-A1 | 1,2,4-Trioxanes and 1,2,4-trioxepanes | O'NEILL PAUL M | 2005-11-17 | — | — | US | disclosed |
| WO-2004028476-A2 | ARTEMISININ-DERIVED TRIOXANE DIMERS | JOHNS HOPKINS UNIVERSITY (US) | 2004-04-08 | — | — | WO | disclosed |
| CN-1117629-C | Carbonylation catalyst system | DSM NV (NL) | 2003-08-13 | — | — | CN | disclosed |
| US-6586464-B2 | Artemisinin analogs having antimalarial, antiproliferative, and antitumor activities and chemoselective methods of making the same | JOHNS HOPKINS UNIVERSITY | 2003-07-01 | — | — | US | disclosed |
| EP-1150984-A1 | ARTEMISININ ANALOGS HAVING ANTIMALARIAL, ANTIPROLIFERATIVE, AND ANTITUMOR ACTIVITIES AND CHEMOSELECTIVE METHODS OF MAKING THE SAME | Hauser, Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-6297272-B1 | Artemisinin analogs having antimalarial antiproliferative and antitumor activities and chemoselective methods of making the same | HAUSER, INC. | 2001-10-02 | — | — | US | disclosed |
| WO-2000042046-A9 | ARTEMISININ ANALOGS HAVING ANTIMALARIAL, ANTIPROLIFERATIVE, AND ANTITUMOR ACTIVITIES AND CHEMOSELECTIVE METHODS OF MAKING THE SAME | HAUSER INC (US) | 2001-09-20 | — | — | WO | disclosed |
| CN-1070169-C | Process for carbonylation of butadiene or butadiene derivative | DSM NV (NL) | 2001-08-29 | — | — | CN | disclosed |
| CN-1297433-A | Processes for producing epsilon-caprolactams | UNION CARBIDE CHEM PLASTIC (US) | 2001-05-30 | — | — | CN | disclosed |
| WO-2000042046-A1 | ARTEMISININ ANALOGS HAVING ANTIMALARIAL, ANTIPROLIFERATIVE, AND ANTITUMOR ACTIVITIES AND CHEMOSELECTIVE METHODS OF MAKING THE SAME | HAUSER, INC. (US) | 2000-07-20 | — | — | WO | disclosed |
| CN-1252015-A | Carbonylation catalyst system | DSM NV (NL) | 2000-05-03 | — | — | CN | disclosed |
| CN-1138021-A | Process for carbonylation of butadiene or butadiene derivative | DSM NV (NL) | 1996-12-18 | — | — | CN | disclosed |
| CN-1044475-A | Epoxy-aromatic polysiloxane composition | M & T CHEMICALS INC (US) | 1990-08-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256184-A1 | 1,2,4-Trioxanes and 1,2,4-trioxepanes | TALDO1, THPO, ALOX12 | TSHR 1949/4885 |
| US-20060142377-A1 | Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high selectively, stability and efficacy and methods of making the same | HCCS, ACIN1, ADH1A | TSHR 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.